The immune system can't do what we thought it could
Deep within the human immune system, a consistent molecular boundary has been discovered that quietly limits the body's ability to defend the places where respiratory viruses first arrive. Scientists at the University of Surrey and University College London, mapping the immune responses of fifteen volunteers across six months of mRNA vaccination, found that a gene called IGHG2 acts as a near-universal stopping point in the process by which immune cells choose what kind of antibody to produce. The consequence is that current vaccines build strong defenses in the bloodstream but leave the nose, throat, and lungs comparatively unguarded—not because the vaccines are poorly made, but because the immune system itself has a boundary that has not yet been asked to cross.
- Vaccinated people can still catch and spread respiratory viruses because the immune system reliably fails to produce IgA2, the antibody that guards the mucosal surfaces where viruses actually enter.
- A gene called IGHG2 acts as a near-universal checkpoint in immune cell development, halting the progression toward mucosal antibody production in every single participant studied—regardless of vaccination.
- The discovery overturns two assumptions at once: class switching and antibody refinement were thought to happen together, but the study shows they are separated by months, with meaningful fine-tuning not beginning until six months after the first dose.
- An unexpected surge of 'double negative' B cells after the second vaccine dose raises new questions about whether mRNA platforms inadvertently activate immune pathways that bypass the normal antibody refinement process.
- Researchers have released their full dataset publicly, and the field is now oriented toward a single urgent question: can vaccines be engineered to push past the IGHG2 barrier and deliver protection where it is most needed?
Scientists at the University of Surrey, working with colleagues at University College London, have mapped the human immune response to an mRNA vaccine in finer detail than ever before—and found a consistent biological boundary that may explain one of the pandemic era's most frustrating puzzles: why vaccinated people can still become infected and transmit respiratory viruses.
The study followed fifteen healthy adults who had never encountered SARS-CoV-2, tracking their immune responses across more than twenty timepoints over six months after two doses of the Moderna vaccine. From nearly 3.8 million antibody gene sequences and single-cell analysis of the B cells that produce antibodies, the researchers built an unusually precise picture of how a first-time immune response unfolds.
At the center of the findings is a process called class switch recombination, in which B cells permanently change the type of antibody they manufacture. Rather than moving freely between antibody types, the researchers found that cells follow a strict sequence along the genome—and that this sequence consistently stalled at a gene called IGHG2. Beyond that point, switching to other antibody types was rare and confined to a small number of specific B cell subtypes. The barrier appeared in every participant and seemed independent of the vaccine itself, suggesting it reflects something fundamental about how human immunity is structured.
The practical consequence is that the mRNA vaccine produced strong IgG1 antibodies, which circulate in the blood and reduce disease severity, but very little IgA2—the antibody type that protects the mucosal surfaces of the nose, throat, and lungs. Lead author Deborah Dunn-Walters noted that while the rules of class switching have long been known, the precision and universality of this particular barrier in a first-time response is new knowledge that changes how researchers must think about vaccine design.
The study also separated two processes previously assumed to occur together. Class switching happened rapidly in the weeks after vaccination, but the gradual refinement of antibodies to better recognize their target did not meaningfully begin until six months after the first dose—a finding with direct implications for how booster timing should be considered.
A further surprise came after the second dose, when a population of B cells known as 'double negative' cells expanded substantially. These cells have been associated with chronic infection, autoimmune conditions, and aging, and collaborator Claudia Mauri suggested the mRNA platform may inadvertently favor them by triggering immune activation that bypasses the germinal centers where antibodies are normally shaped and refined. The complete dataset has been made publicly available, and the field's next challenge, as the researchers frame it, is determining whether vaccines can be deliberately engineered to cross the IGHG2 boundary and generate the mucosal protection that current designs leave largely unbuilt.
Researchers have identified a consistent biological wall in the human immune system that prevents it from producing the specific antibodies needed to protect the nose, throat, and lungs from respiratory viruses. The discovery, led by scientists at the University of Surrey working with colleagues at University College London, could reshape how the next generation of vaccines are designed—particularly those meant to stop infection at the point where viruses actually enter the body.
The team studied fifteen healthy adults who had never encountered SARS-CoV-2 before. These volunteers received two doses of the Moderna mRNA vaccine, and researchers collected blood samples every other day for the first three weeks, then at weeks eight, ten, and twelve, and again six months later. The result was an extraordinarily detailed map of how the human immune system responds to a vaccine for the first time, built from nearly 3.8 million antibody gene sequences and single-cell analysis of the B cells that manufacture antibodies.
At the heart of the findings is a process called class switch recombination, in which B cells permanently change the type of antibody they produce. The researchers discovered that this switching follows a strict path along the genome, with cells moving through antibody types in a fixed sequence rather than jumping freely between them. Across every single participant, the process consistently halted at a gene called IGHG2, roughly halfway through the sequence. Beyond that point, switching to other antibody types was rare and happened only in a small number of specific B cell subtypes. Remarkably, this barrier appeared regardless of whether the cells were responding to the vaccine or not, suggesting it is a fundamental feature of how human immunity works.
The practical consequence is significant. The mRNA vaccine generated a robust response in IgG1 antibodies, which circulate through the bloodstream and reduce disease severity. But it produced very little IgA2—the antibody type that guards mucosal surfaces. Since respiratory viruses including SARS-CoV-2 enter through the nose, throat, and lungs, the weak IgA2 response may explain why vaccinated people can still become infected and transmit the virus to others. Deborah Dunn-Walters, the lead author and a professor at Surrey, noted that while scientists have long known antibody class switching follows biological rules, the consistency and precision of this barrier at IGHG2 in a first-time response is new. "The detail we have here changes how we think about what the immune system can and cannot do when encountering a vaccine for the first time," she said.
The research also upended a long-standing assumption about how antibodies are refined. Class switching and somatic hypermutation—the process by which antibodies are progressively tuned to better recognize their target—were thought to happen simultaneously. Instead, class switching occurred rapidly in the weeks after vaccination, but meaningful antibody refinement did not appear until six months after the first dose. The two processes were separate events. Franca Fraternali, a collaborator at University College London, observed that B cells switched their antibody types very efficiently early on, but the fine-tuning of those antibodies barely began until much later. That separation has implications for how researchers think about the timing of booster doses.
Another unexpected finding emerged after the second vaccine dose: B cell subtypes known as "double negative" cells expanded substantially among the antigen-specific B cells. These cells have been linked to chronic infections, autoimmune conditions, and aging. Claudia Mauri, another collaborator at University College London, suggested that the mRNA platform may inadvertently favor these non-traditional B cells because it triggers an interferon signal that promotes a type of immune activation bypassing the germinal centers where antibodies are normally refined. The researchers have made their complete dataset—combining bulk and single-cell gene sequencing with flow cytometry and serology across more than twenty timepoints per participant—publicly available to support future work in vaccine design and B cell biology. The next question, as Dunn-Walters framed it, is whether scientists can engineer vaccines that selectively push past this barrier to produce stronger protection where it matters most.
Citas Notables
The detail we have here changes how we think about what the immune system can and cannot do when encountering a vaccine for the first time.— Deborah Dunn-Walters, Professor, University of Surrey
These B cells were switching their antibody types very efficiently in the early weeks after vaccination, but the fine-tuning of those antibodies was barely underway until much later.— Franca Fraternali, University College London
La Conversación del Hearth Otra perspectiva de la historia
So if the vaccine is working—if it's generating antibodies—why does this barrier matter so much?
Because it's generating the wrong kind of antibodies for the job. IgG1 antibodies are good at reducing how sick you get, but they circulate in the blood. IgA2 is what actually stands guard at the surfaces where the virus enters. The barrier stops the immune system from making enough of that second type.
And this barrier exists in everyone? It's not a flaw in the vaccine design?
That's what makes it so significant. It appears in every person they studied, regardless of whether the immune cells were responding to the vaccine or something else. It's a fundamental constraint of how human immunity operates, not a vaccine problem. Which means we can't just tweak the current approach—we have to work around it.
The study mentions these "double negative" B cells expanding after the second dose. Should people be concerned about that?
It's worth watching carefully. These cells show up in chronic infections and autoimmune conditions, so their expansion isn't ideal. But the researchers aren't saying the vaccine caused harm—they're saying the mRNA platform seems to favor these cells in a way we didn't expect. That's a question for future research.
What changes if researchers can overcome this barrier?
Everything about respiratory vaccine protection. Right now, vaccinated people can still catch and spread respiratory viruses because the mucosal defenses are weak. If you could push past that barrier and generate strong IgA2 responses, you'd have protection where it actually matters—at the point of infection.
How long until we see a vaccine designed around this discovery?
That's the work ahead. Understanding the barrier is the first step. Designing a vaccine that overcomes it is the next one. The researchers have made all their data public, so the field can start working on it now.